3nfa: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design== | ==Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design== | ||
<StructureSection load='3nfa' size='340' side='right' caption='[[3nfa]], [[Resolution|resolution]] 1.95Å' scene=''> | <StructureSection load='3nfa' size='340' side='right' caption='[[3nfa]], [[Resolution|resolution]] 1.95Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3nfa]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[3nfa]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/9hiv1 9hiv1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3NFA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3NFA FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene>, <scene name='pdbligand=CBJ:6-[(5-BROMO-2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)METHYL]-2,3-DIHYDRO-1,4-BENZODIOXINE-5-CARBOXYLIC+ACID'>CBJ</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene>, <scene name='pdbligand=CBJ:6-[(5-BROMO-2,3-DIOXO-2,3-DIHYDRO-1H-INDOL-1-YL)METHYL]-2,3-DIHYDRO-1,4-BENZODIOXINE-5-CARBOXYLIC+ACID'>CBJ</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1bhl|1bhl]], [[1bi4|1bi4]], [[1biu|1biu]], [[1ex4|1ex4]], [[1k6y|1k6y]], [[3nf6|3nf6]], [[3nf7|3nf7]], [[3nf8|3nf8]], [[3nf9|3nf9]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1bhl|1bhl]], [[1bi4|1bi4]], [[1biu|1biu]], [[1ex4|1ex4]], [[1k6y|1k6y]], [[3nf6|3nf6]], [[3nf7|3nf7]], [[3nf8|3nf8]], [[3nf9|3nf9]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3nfa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3nfa OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3nfa RCSB], [http://www.ebi.ac.uk/pdbsum/3nfa PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3nfa FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3nfa OCA], [http://pdbe.org/3nfa PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3nfa RCSB], [http://www.ebi.ac.uk/pdbsum/3nfa PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3nfa ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 15: | Line 16: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 3nfa" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
*[[Retroviral Integrase|Retroviral Integrase]] | *[[Retroviral Integrase|Retroviral Integrase]] | ||
== References == | == References == | ||
| Line 23: | Line 24: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Deadman, J J]] | [[Category: Deadman, J J]] | ||
[[Category: Newman, J]] | [[Category: Newman, J]] | ||
Revision as of 03:18, 26 January 2017
Structural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based designStructural basis for a new mechanism of inhibition of HIV integrase identified by fragment screening and structure based design
Structural highlights
Publication Abstract from PubMedBACKGROUND: HIV-1 integrase is a clinically validated therapeutic target for the treatment of HIV-1 infection, with one approved therapeutic currently on the market. This enzyme represents an attractive target for the development of new inhibitors to HIV-1 that are effective against the current resistance mutations. METHODS: A fragment-based screening method employing surface plasmon resonance and NMR was initially used to detect interactions between integrase and fragments. The binding sites of the fragments were elucidated by crystallography and the structural information used to design and synthesize improved ligands. RESULTS: The location of binding of fragments to the catalytic core of integrase was found to be in a previously undescribed binding site, adjacent to the mobile loop. Enzyme assays confirmed that formation of enzyme-fragment complexes inhibits the catalytic activity of integrase and the structural data was utilized to further develop these fragments into more potent novel enzyme inhibitors. CONCLUSIONS: We have defined a new site in integrase as a valid region for the structure-based design of allosteric integrase inhibitors. Using a structure-based design process we have improved the activity of the initial fragments 45-fold. Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design.,Rhodes DI, Peat TS, Vandegraaff N, Jeevarajah D, Le G, Jones ED, Smith JA, Coates JA, Winfield LJ, Thienthong N, Newman J, Lucent D, Ryan JH, Savage GP, Francis CL, Deadman JJ Antivir Chem Chemother. 2011 Mar 7;21(4):155-68. PMID:21602613[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||